Inlyta (axitinib)
- Region
- 🇪🇺 EU
- Active substance
- axitinib
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Carcinoma, Renal Cell
- CHMP opinion
- Thu 24 May 2012
- EU approval
- Mon 03 Sep 2012
- Application
- EMEA/H/C/002406
- ATC
- L01EK01
- Official record
- www.ema.europa.eu
Indication
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Axitinib Accord Authorised · Accord Healthcare S.L.U.
Follow Inlyta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.